Seeking a possible new target for lymphoma treatment
Cancer types:
Lymphoma
Project period:
–
Research institute:
European Institute of Oncology (IEO)
Award amount:
£234,000
Location:
Italy
Professor Bruno Amati and his team are investigating new ways to target a type of fast-growing lymphoma that can be particularly difficult to treat.
Hope for the future
Diffuse large B cell lymphoma is a type of blood cancer that affects our white blood cells. Approximately 5,000 people are diagnosed with this lymphoma in the UK every year. It can be quite aggressive, and although many cases can be successfully treated, others are harder to clear and sadly, can sometimes come back.
Professor Amati has a bright idea about a new way to treat diffuse large B cell lymphoma. The team are focusing on a particular molecular mechanism that some aggressive types of lymphoma cell seem to rely on heavily to survive and grow. They think this mechanism, called ‘nonsense-mediated decay’, could be the key to finding a new way to target the disease. If their hunch proves to be right, this could be the first step towards a new treatment option for patients.
Meet the scientist
Professor Amati has always been interested in "oncogenes" - those genes that have been shown to be super-activated and to drive disease progression in cancer. What did these genes actually do in cells? And how did they contribute to normal development and disease? He always had plenty of questions, and the answers seemed to be lurking around the corner... a pretty irresistible attraction for a young biologist! He has worked on this topic for over three decades now, around the world - in Switzerland, the UK, the USA and now Italy - helping to find the answers.
The science
All cells need special mechanisms to help regulate how they survive and grow, and nonsense-mediated decay is one of these mechanisms. It acts as a sort of ‘quality control’ for the genetic material in our cell, and helps to make sure that faulty genetic molecules are destroyed before they can cause any harm.
During earlier experiments, Professor Amati and his team gathered some exciting data suggesting that nonsense-mediated decay may actually be incredibly important for some types of lymphoma cells.
This finding was unexpected, and at first the team were surprised. Now, thanks to funding from our Curestarters, the researchers can build on their exciting new finding and investigate in greater depth exactly how and why some lymphoma cancer cells rely on nonsense-mediated decay. The team then hope to search for new drugs which could interfere with this process.
If successful, their work should help to build up a detailed picture of a possible new vulnerability in B cell lymphoma. It will hopefully lead the way to future lymphoma cures, and possibly even cures for other cancers with similar vulnerabilities.
Worldwide Cancer Research’s funding mission is so precious to all of us: funding today’s basic research, no matter where, will impact tomorrow’s cures.
Active United Kingdom
Lymphoma
This project will explore a cancer mutation which could be key to finding new way stop cancer progressing, opening the door to future new treatments.
Researcher: Professor Richard Jenner
A new way to switch anti-cancer genes back on
Active Switzerland
Lymphoma
Understanding how healthy cells support the survival and growth of lymphoma will ultimately lead to the development of essential new treatments.
Researcher: Professor Davide Rossi
How genetic mutations in healthy blood cells can help drive lymphoma development
Active Ireland
Lymphoma
This project hopes to lead to a way to stop cancer cells from becoming resistant to a type of targeted treatment, so that the therapy works for more people.
Researcher: Professor Adrian Bracken
Maximising the effectiveness of a targeted therapy for non-Hodgkin lymphoma